Literature DB >> 20665981

Neoadjuvant targeted therapy in renal cell carcinoma.

Roberto Iacovelli, Cristina Raimondi, Antonella Palazzo, Enrico Cortesi, Giuseppe Procopio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20665981     DOI： 10.1038/nrurol.2010.2-c1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Kidney cancer: neoadjuvant targeted therapies in renal cell carcinoma.

Authors:  Vincenzo Ficarra; Giacomo Novara
Journal:  Nat Rev Urol       Date:  2010-02       Impact factor: 14.432

2.  Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

Authors:  R Thiam; L S Fournier; L Trinquart; J Medioni; G Chatellier; D Balvay; B Escudier; C Dromain; C A Cuenod; S Oudard
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.

Authors:  Amnon Zisman; Allan J Pantuck; Jeffery Wieder; Debby H Chao; Fredrick Dorey; Jonathan W Said; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

5.  Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.

Authors:  Arie S Belldegrun; Tobias Klatte; Brian Shuch; Jeffrey C LaRochelle; David C Miller; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz F Kabbinavar; Jean B Dekernion; Allan J Pantuck
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

6.  Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Authors:  A A M van der Veldt; M R Meijerink; A J M van den Eertwegh; J B A G Haanen; E Boven
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

7.  Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Axel Bex; Gijsbert de Gast; John B A G Haanen; Epie Boven
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.